Prescriptive natural killer cell-based immunotherapy for cancer
Prescriptive natural killer cell-based immunotherapy for cancer
批准号:
475366
负责人:
Carter Emily
金额:
$7.65万
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-11-01 至 2025-11-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Leukemia, a cancer of the blood, can only be cured by a stem cell transplant, but 40% of people with this cancer relapse even after a transplant. In patients that do not relapse, natural killer (NK) cells, a type of white blood cell, can kill leukemia cel
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金